Phenotypic Differences of Gastric Cancer according to the Helicobacter pylori Infection in Korean Patients by Park, Dong-Wook et al.
Copyrights © 2010 by The Korean Gastric Cancer Association www.jgc-online.org
Original Article
Introduction
Helicobacter was discovered in 1983,(1) but it was not until 1989 
that it was suggested that H. pylori plays a role in the development 
of precancerous lesions.(2) Further, it has been suggested that H. 
pylori is associated with gastric cancer based on the findings that 
H. pylori is more prevalent in patients with atrophic gastritis than 
a control group.(3) In 1994, the International Agency for Research 
on Cancer (IARC) classified H. pylori as a definite carcinogenic 
factor (Group I) in humans.(4) In a meta-analysis, it was reported 
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that the risk of gastric cancer in the population with H. pylori in-
fection increased from 1.81- to 2.24-fold and greater differences 
were shown in the young age groups.(5) It has been reported that 
in the population with H. pylori infection, the incidence of gastric 
cancer is higher in the cytotoxin-associated gene A (CagA)-positive 
group.(6) In Japanese and Korean patients with gastric cancer, the 
CagA-positive rate has been reported to be high.(7) It has been 
reported that the mechanism by which H. pylori induces gastric 
cancer involves the induction of chronic inflammation in the gastric 
mucosa, and while progressing to through pre-cancerous lesions 
(atrophic gastritis, metaplasia, and dysplasia), H. pylori induces mu-
tation of genes.(8) It has been hypothesized that a similar mecha-
nism is involved in the development of colorectal cancer from ad-
enoma to adenocarcinoma; specifically, the process of activation of 
oncogenes, suppression of tumor suppressor genes, and mismatch 
repair of DNA occurs, resulting in the development of gastric can-
cer.(9) Korea is an area where the H. pylori infection rate is high, Phenotypic Differences of Gastric Cancer
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and thus to examine the effect of H. pylori on gastric cancer, vari-
ous clinical factors of patients with gastric cancer according to the 
status of infection and the pathologic factors of gastric cancer were 
analyzed. 
Materials and Methods
Among patients diagnosed with gastric adenocarcinoma who 
underwent gastrectomies at the Korea Cancer Center Hospital 
between September 2006 and May 2010, 161 patients in whom 
H. pylori infection was confirmed by the rapid urease test (RUT) 
method performed on the gastric mucosa obtained by biopsy im-
mediately after gastrectomy were recruited. Among them 161 pa-
tients, 2 patients who received neoadjuvant chemotherapy, 1 patient 
with remnant gastric cancer, and 3 patients who did not undergo 
radical resection were excluded; thus, the study was conducted on 
155 patients. A past history of H. pylori and eradication treatments 
were assessed by questionnaire, and patients with a past history of 
infection were excluded. 
In the current study, the status of H. pylori infection was as-
sessed by the RUT. As we reported previously,(10) this method is 
to biopsy the mucosa of the antrum and body of the stomach (one 
each), from resected specimens immediately after gastrectomy, 
add to a RUT kit (Pronto Dry
Ⓡ kit; Medical Instruments Corp., 
Solothum, Switzerland), fix, and read the positivity based on color 
changes within 24 hours. 
The clinical characteristic of the patients (age, gender, and car-
cinoembryonic antigen and CA19-9 levels) were recorded. Using 
an enzyme immunoassay kit (Pyloriset EIA-G; Orion Diagnostica, 
Espoo, Finland), serum anti-H. pylori immunoglobulin G (anti-
HP IgG) was measured, and a value ＜20 U/ml was read as nega-
tive. Early gastric cancer (EGC) or advanced gastric cancer (AGC), 
the gross type, tumor size, vertical and horizontal size of tumor, 
histologic type according to the WHO classification, tissue type 
according to the Lauren’s classification, lymphatic invasion, venous 
invasion, and perineural invasion were examined. In addition, the 
depth of invasion, lymph node metastasis status, peritoneal wash-
ing cytology results, and the TNM disease stage according to the 
6th(11) and 7th editions of the UICC(12) were examined.
Univariate analysis was performed for nominal variables by a 
chi-square test. For the categories in which ＞5 expected values 
of cells were ＜70% were analyzed by the Fisher’s exact test. For 
multivariate analysis, multiple logistic regression model was used. 
A P-value＜0.05 was considered to be statistically significant. 
Table 1. Comparison of clinicopathologic features between HP 
positive gastric cancer and HP negative gastric cancer patients in 
Rapid Urease Test
N H. pylori (+)  H. pylori (-) P-value
Cases 155 137 (88.4) 18 (11.6)
Sex 
  Male
  Female
99
56
86 (86.9)
51 (91.1)
13 (13.1)
5 (8.9)
NS
Age
  <60 years
  ≥60 years
58
97
50 (86.2)
87 (89.7)
8 (13.8)
10 (10.3)
NS
CEA
  ≤5 ng/ml*
  >5 ng/ml
143
12
128 (89.5)
9 (75.0)
15 (10.5)
3 (25.0)
NS
CA19-9
  ≤37 U/ml 
  >37 U/ml
143
12
127 (88.8)
10 (83.3)
16 (11.2)
2 (16.7)
NS
HP IgG
  Positive
  Negative
125
30
112 (89.6)
25 (83.3)
13 (10.4)
5 (16.7)
NS
EGC vs. AGC
  EGC
  AGC
74
81
70 (94.6)
67 (82.7)
4 (5.4)
14 (17.3)
0.021
EGC
† gross types
  Type  I/IIa
  Type  IIb/IIc/III
16
58
13 (81.3)
57 (98.3)
3 (18.8)
1 (1.7)
0.008
AGC
† gross types
  Type I/II
  Type III/IV/V
16
65
16 (100.0)
51 (78.5)
0 (0.0)
14 (21.5)
0.041
Tumor size
  <4.0 cm
  ≥4.0 cm
84
71
77 (90.5)
60 (85.9)
7 (9.5)
11 (14.1)
NS
‡
Longitudinal location
  Upper third
  Middle third
  Lower third
  Whole
17
35
85
18
15 (88.2)
30 (85.7)
77 (90.6)
15 (83.3)
2 (11.8)
5 (14.3)
8 (9.4)
3 (16.7)
NS
‡
Circumferential location
  Lesser curvature
  Greater curvature
  Anterior wall
  Posterior wall
  Encircling
68
32
25
24
6
62 (91.2)
27 (84.4)
21 (84.0)
21 (87.5)
6 (100.0)
6 (8.8)
5 (15.6)
4 (16.0)
3 (12.5)
0 (0.0)
NS
‡
WHO classifi  cation
  Pap
  Well
  Mod
  Poorly
  Mucinous
  SRC
  Others
3
17
63
38
8
24
2
3 (100.0)
14 (82.4)
59 (93.7)
31 (81.6)
5 (62.5)
24 (100.0)
1 (50.0)
0 (0.0)
3 (17.6)
4 (6.3)
7 (18.4)
3 (37.5)
0 (0.0)
1 (50.0)
0.007
‡Park DW, et al.
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SPSS (ver.14; SPSS Inc., Chicago, IL, USA) was used for statistical 
analyses.
Results
Among 155 patients, 99 were male, 56 were female, and the 
mean age was 61.6 and 58.1 years, respectively. Ninety-seven pa-
tients were ＞60 years of age and 58 patients were ＜60 years of 
age. One hundred thirty-seven patients were H. pylori-positive 
based on the RUT test, for an 88.4% infection rate.
The clinicopathologic factors of H. pylori-positive and 
-negative gastric cancer patients were compared (Table 1). In 
the H. pylori-negative group, AGC was prevalent (P=0.021), 
Table 1. Continued
N H. pylori (+)  H. pylori (-) P-value
Lauren classifi  cation
  Intestinal
  Mixed
  Diff  use
149
80
59
10
131 (87.9)
70 (87.5)
53 (89.8)
8 (80.0)
18 (12.1)
10 (12.5)
6 (10.2)
2 (20.0)
NS
Lymphatic invasion
  Absence 
  Presence
89
66
78 (87.6)
59 (89.4)
11 (12.4)
7 (10.6)
NS
Vascular invasion
  Absence 
  Presence
145
10
128 (88.3)
9 (90.0)
17 (11.7)
1 (10.0)
NS
Perineural invasion
  Absence 
  Presence
111
44
99 (89.2)
38 (86.4)
12 (10.8)
6 (13.6)
NS
Depth of invasion 
  M
  SM
  MP
  SS
  SE
  SI
37
37
29
20
30
2
36 (97.3)
34 (91.9)
23 (79.3)
18 (90.0)
25 (83.3)
1 (50.0)
1 (2.7)
3 (8.1)
6 (20.7)
2 (10.0)
5 (16.7)
1 (50.0)
   NS
‡
Lymph node metastasis
  Negative 
  Positive
93
62
 
84 (90.3)
53 (85.5)
 
9 (9.7)
9 (14.5)
NS
Cytology
  Negative 
  Positive
140
15
 
125 (89.3)
12 (80.0)
 
15 (10.7)
3  (20.0)
NS
TNM stage (6th)
  Stage I
  Stage II
  Stage III
  Stage IV
98
24
22
11
91 (92.9)
17 (70.8)
20 (90.9)
9 (81.8)
7 (7.1)
7 (29.2)
2 (9.1)
2 (18.2)
0.021
‡
TNM stage (7th)
  Stage I
  Stage II
  Stage III
  Stage IV
82
35
23
15
76 (92.7)
27 (77.1)
22 (95.7)
12 (80.0)
6 (7.3)
8 (22.9)
1 (4.3)
3 (20.0)
0.046
‡
HP = H. pylori; NS = not significant; CEA = carcinoembrionic 
antigen; CA= carbohydrate antigen; EGC = early gastric cancer; AGC 
= advanced gastric cancer; SRC = signet ring cell; M = mucosa; SM 
= submucosa; MP = muscularis propria; SS = subserosa; SE = serosa 
exposure; SI = serosa invasion. *CEA≤10 ng/ml in smoker; 
†EGC and 
AGC were categorized according to the histological depth of invasion; 
Values in parentheses are percentages; 
‡P-value in Fisher’s exact test.
Table 2. Comparison of clinicopathologic features between EGC 
and AGC
N
EGC AGC
P-value
N=74 N=81
Tumor size
  <4 cm
  ≥4 cm
84
71
62 (73.8)
12 (16.9)
22 (26.2)
59 (83.1)
<0.001
Longitudinallocation
  Upper third
  Middle third
  Lower third
  Whole
17
35
85
18
6 (35.3)
17 (48.6)
50 (58.8)
1 (5.6)
12 (64.7)
18 (51.4)
35 (41.2)
19 (94.4)
<0.001
WHO classifi  cation
  Diff  *
  Undiff   
†
83
72
46 (55.4)
28 (38.9)
37 (44.6)
34 (61.1)
0.040
Lymphatic invasion
  Absence
  Presence
89
66
60 (67.4)
14 (21.2)
29 (32.6)
52 (78.8)
0.040
Venous invasion
  Absence
  Presence
145
10
73 (50.3)
1 (10.0)
72 (49.7)
9 (90.0)
0.013
Perineural invasion
  Absence
  Presence
111
44
72 (64.9)
2 (4.5)
39 (35.1)
42 (95.5)
<0.001
CA19-9
  ≤37 U/ml 
  >37 U/ml
143
12
73 (51.0)
1 (8.3)
70 (49.0)
11 (91.7)
0.004
HP infection in RUT
  HP (+)
  HP (-)
137
18
70 (51.1)
 4 (22.2)
67 (48.9)
14 (77.8)
0.021
EGC = early gastric cancer; AGC = advanced gastric cancer; CA= 
carbohydrate antigen; HP = H. pylori; RUT = rapid urease test.   
*Papillary, tubular adenocarcinoma, well andmoderately diff  erentiated; 
†Tubular adenocarcinoma poorly differentiated, Mucinuous 
adenocarcinoma, signet ring cell carcinoma, undifferentiated 
adenocarcinoma and others; Values in parentheses are percentages.Phenotypic Differences of Gastric Cancer
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and the histologic type according to the WHO classification 
also showed a significant difference between the two groups 
(P=0.007). The signet ring cell-type was present in 24 patients, 
all of whom were in the H. pylori-positive group. The poorly 
differentiated tubular- and mucinous-type were more prevalent 
in the H. pylori-negative group. Based on macroscopic findings, 
tumors were divided into EGC and AGC and compared. It was 
shown that in the H. pylori-negative group, type I or IIa EGC 
was abundant (P=0.005) and the frequency of types III, IV, and V 
AGC was high (P=0.041). In addition, the TNM disease stage ac-
cording to the classification of the 6th (P=0.021) and 7th editions 
of the UICC (P=0.046) showed a significant difference. The patient 
gender, age, size or location of the tumor, tumor markers, and the 
results of immunoserological tests for H. pylori between the two 
groups were not significantly different.
The patients were divided into EGC (74 patients) and AGC 
groups (81 patients) (Table 2). There were no differences in gender, 
age, carcinoembryonal antigen level, and H. pylori immunosero-
logical tests between the two groups. Significant factors were tumor 
size (P＜0.001), location (P＜0.001), histologic type (P=0.040), 
lymphatic invasion (P=0.040), venous invasion (P=0.013), and peri-
neural invasion (P＜0.001). In addition, the elevation of CA19-9 
(P=0.004) and H. pylori infection (P=0.021) also showed a signifi-
cant difference, and the ratio of AGC was high in the H. pylori-
negative group (77.8%). Multivariate analysis was performed on the 
variables shown to be significant based on univariate analysis (Table 
3). Independent risk factors for AGC included lymphatic invasion 
(odds ratio [OR], 3.353; 95% confidence interval [CI], 1.264~8.890), 
perineural invasion (OR, 28.192; 95% CI, 5.667~140.251), tumor 
size (OR, 7.026; 95% CI, 2.639~18.701), and H. pylori-negative 
(OR, 7.153; 95% CI, 1.707~29.975).
Discussion
In a nested-case control study conducted in many countries, 
the rate of H. pylori infection in the gastric cancer and control 
groups was reported to be 81.2% and 66.1%, respectively.(13) In a 
Japanese study, the infection rate in the gastric cancer and control 
groups was reported to be 91.1% and 75.6%, respectively.(14) In a 
prospective study, gastric cancer patients existed in the H. pylori-
positive group only, and the infection rate in the gastric cancer 
group was shown to be 100%.(15) In a nested-case control study 
conducted in Korea, the status of H. pylori infection in gastric can-
cer patients was examined, and 83.7% patients were positive.(16) 
This was not greatly different from the results of the current study 
(88.4%) that measured the rate of H. pylori infection by RUT only. 
In the current study, analyzed according to age and gender, the rate 
of H. pylori infection did not show a significant difference, and 
other cinical factors also did not show significant differences. In 
the current study, the status of H. pylori infection was determined 
by the results of the RUT only. In comparison with the status of H. 
pylori infection assessed by serological tests, a significant difference 
was not shown. In the 155 patients, the positive prediction rate by 
the RUT was shown to be high, but a significant difference was not 
shown, which may may be due to patients in whom the serological 
tests were false-negative, false-positive RUT, or harvested speci-
mens that were H. pylori-positive, but H. pylori was absent. Since 
each study assessed the infection rate of H. pylori using different 
methods, a direct comparison was difficult.
When infected with H. pylori, inflammation develops in the 
gastric mucosa due to the infiltration and activation of various 
inflammatory cells resulting in the injury and degeneration of the 
epithelium of the stomach. Initially, H. pylori induces the produc-
tion of various cytokines through the direct contact with gastric ep-
ithelial cells, and among them, IL-8 strongly induces leucocytes.(17) 
In addition, H. pylori infection induces diverse immunologic reac-
tions. H. pylori induces the synthesis of auto-antibodies in parietal 
cells,(18) which is thought to be a factor inducing the development 
of atrophic gastritis after H. pylori infection and the progression of 
gastric cancer. H. pylori infection induces the infiltration of vari-
ous inflammatory cells, and through this, a large amount of active 
oxidants are released, NO production is accelerated by the elevation 
of the expression of iNOS of infected epithelial cells, ammonia is 
Table 3. Multivariate analysis between EGC and AGC. Binary 
logistic regression, backward Conditional method
Variable P-value Odds ratio  95% CI
HP infection in RUT
  (-) vs. (+)
0.007 7.153 1.707~29.975
Tumor size
  ≥4.0 cm vs. <4.0 cm
<0.001 7.026 2.639~18.701
Lymphatic invasion
  Presence vs. Absence 
0.015 3.353 1.264~8.890
Perineural invasion
  Presence vs. Absence
<0.001 28.192 5.667~140.251
EGC = early gastric cancer; AGC = advanced gastric cancer; CI = 
confi  dence interval; HP = H. pylori; RUT = rapid urease test.Park DW, et al.
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degraded by urease, the reactive oxidant NH2Cl is produced, NH2Cl 
penetrates cell membranes freely and oxidizes intracellular compo-
nents, and consequently induces gastric cancer.(19) 
Parsonnet et al.(20) reported that gastric cancer was classified 
into intestinal- and diffuse-type gastric cancer and found that in 
the H. pylori infection group, intestinal-type gastric cancer was 
significantly more abundant. In the current study, the association 
between H. pylori infection and the diffuse-type gastric cancer was 
not significantly different from the intestinal-type gastric cancer 
classified according to the Lauren’s classification. In the current 
study, when gastric cancer was classified by histologic morphol-
ogy according to the WHO classification, a significant difference 
between the two groups was shown. The poorly undifferentiated 
tubular- and mucious-type in the negative group was 38.9% (7/18) 
and 16.7% (3/18), respectively, and it was shown to be relatively 
more prevalent. Interestingly, 100% signet ring cell-type was de-
tected in the H. pylori-positive group, and such results could be 
considered in connection to the high incidence of the signet cell-
type in Korean patients with gastric cancer.(21) Tatsuta et al.(22) 
reported that H. pylori infection was significantly more abundant 
in well-differentiated tumors in patients with EGC. In the current 
study, the WHO classification was broadly divided into the dif-
ferentiation group (papillary-, well differentiated-, and moderately 
differentiated tubular-type) and the undifferentiated group (poorly 
differentiated tubular-, mucinous-, and the signet ring cell-type) 
and compared; such a difference was not detected.
The signet cell-type occurs only in the H. pylori-positive group. 
Therefore, such results are in agreement with the theory that H. 
pylori infection is associated with the development of the intestinal-
type gastric cancer, as shown previously, and it also shows that H. 
pylori infection is closely associated with the development of signet 
cell-type gastric cancer. Thus, it suggests that H. pylori infection 
could exert effects on the phenotype of gastric cancer cells.
In a meta-analysis that compared EGC with AGC, AGC was 
significantly more prevalent in the H. pylori-negative group in 
comparison with EGC,(5) and our results were similar. In the cur-
rent study, when EGC was examined according to morphology, in 
the H. pylori-negative group, 3 cases were the elevated shape (I/
IIa) and 1 case was the flat/depressed shape (IIb/IIc/III), and the 
H. pylori-positive group 13 of 70 cases had the elevated shape, thus 
the elevated shape was more prevalent.
In a study analyzed EGC according to H. pylori infection, the 
infection rate was significantly low in depressed-type EGC, in-
cluding ulcers.(22) In the current study, in the H. pylori-positive 
group, type IIc EGC was most prevalent, followed by type IIb, IIa, 
I, and III in order. In the negative group, the order was IIa＞I=IIc. 
Nonetheless, in the current study, the association of H. pylori infec-
tion with the depressed-type EGC was examined and significant 
results were not shown. In the current study, the number of the H. 
pylori-negative group, as well as the depressed-type was detected, 
and patients who had an indication for endoscopic submucosal dis-
section were excluded, and thus it is difficult to compare directly 
with the extant literatures. 
The ratio of H. pylori infection in EGC and AGC was described 
previously. In a study which analyzed the status of H. pylori infec-
tion exclusively in AGC, it has been reported that in the positive 
group, Borrmann type I and II were significantly increased.(23) In 
the current study, in the H. pylori-positive group, Borrmann type I 
and II of AGC was 16 of 16 cases (100%), and similar results were 
shown. During the process of the development of gastric cancer, 
when the gastric mucosa progresses to the precancerous lesion 
metaplasia, the pyloric mucosa becomes the environment in which 
H. pylori could not survive. To overcome this, in the current study, a 
biopsy was also performed on the mucosa of the body of the stom-
ach. Examining the causes of such differences, first, it could be hy-
pothesized that as the area of advanced cancer becomes wide, most 
areas of the pyloric mucosa where H. pylori harbors is substituted 
with gastric cancer, and thus becomes the environment where H. 
pylori could not survive, and such a hypothesis could be applicable 
to Borrmann type IV gastric cancer infiltrating the entire stomach.
Second, it could be hypothesized that H. pylori infection itself 
mediates effects on the progression of gastric cancer, and thus in H. 
pylori-positive gastric cancer, the progression is slow; however, in 
H. pylori-negative gastric cancer, rapid progression was shown and 
thus the ratio of advanced gastric cancer becomes high, and the 
biological characteristic of gastric cancer may be aggressive. This 
concurs well to the fact that the prognosis of H. pylori-negative 
patients is poor.(24) In addition, it was observed that in Borrmann 
type I and II gastric cancer, the rate of the H. pylori-positive rate 
was high, which shows the close association of the relatively slow 
progression with H. pylori infection. 
H. pylori is a carcinogenic factor for gastric cancer, and de-
pending on the infection status, differences of the frequency of 
EGC from AGC were shown, and differences of the growth pat-
tern between AGC and EGC were shown. In the histologic clas-
sification, differences were also shown, and thus it appears that the 
status of H. pylori infection exerts effects on the development of 
gastric cancer and the progression pattern. Nonetheless, the rate of Phenotypic Differences of Gastric Cancer
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H. pylori infection is high in Korea, consequently, the number of 
the control group in the current study was small, and thus signifi-
cant differences were not detected in several categories. In the cur-
rent study, the status of H. pylori infection according to serological 
and RUT tests showed great differences, and thus it is thought that 
studies on the method of the diagnosis of H. pylori infection is re-
quired. If more studies are conducted, the clinical course, as well as 
the pattern of progression of gastric cancer according to H. pylori 
infection, could be better elucidated.
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